A5004748937- Cancer-related molecular mechanisms research
- Multiple Myeloma Research and Treatments
- Pharmacological Receptor Mechanisms and Effects
- Adenosine and Purinergic Signaling
- Mycobacterium research and diagnosis
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- MicroRNA in disease regulation
- Neuroscience and Neuropharmacology Research
- Autophagy in Disease and Therapy
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
- Circular RNAs in diseases
- Tryptophan and brain disorders
- Transplantation: Methods and Outcomes
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Stress, Anesthesia, and Immune Response
Dana-Farber Cancer Institute
2022-2024
Harvard University
2024
Eastern University
2024
Northeastern University
2024
Immunogenic cell death (ICD) is a form of by which cancer treatments can induce clinically relevant antitumor immune response in broad range cancers. In multiple myeloma (MM), the proteasome inhibitor bortezomib an ICD inducer and creates durable therapeutic responses patients. However, eventual relapse resistance to appear inevitable. Here, integrating patient transcriptomic data with analysis calreticulin (CRT) protein interactors, we found that GABA type A receptor-associated (GABARAP)...
Abstract In multiple myeloma (MM), the proteasome inhibitor bortezomib (BTZ) triggers immunogenic cell death (ICD), a critical mechanism by which drug stimulates an anti-MM immune response. During ICD, dying cancer releases danger signals like calreticulin (CRT), attract dendritic cells (DCs) to engulf and present its antigens T cells. Cancer may employ several strategies restrain outcome, including interfering with exposure of CRT on surface. Such resistance mechanisms hinder activation...